Neeraj Agarwal

Research interests

Publications

• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

  European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017

• Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)01055-3

• Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2022 · https://doi.org/10.6004/jnccn.2022.0001

• Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03488

• TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03489

• NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

  Journal of the National Comprehensive Cancer Network · 2020 · https://doi.org/10.6004/jnccn.2020.0043

• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2022485

• Olaparib for Metastatic Castration-Resistant Prostate Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1911440

• Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

  JCO Precision Oncology · 2020 · https://doi.org/10.1200/po.19.00345

• Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)31187-9

• Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30907-0

• Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

  JCO Precision Oncology · 2019 · https://doi.org/10.1200/po.18.00283

• Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.02768

• Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903307

• NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

  Journal of the National Comprehensive Cancer Network · 2019 · https://doi.org/10.6004/jnccn.2019.0054

• Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2016.66.7311

• Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2013.51.7417

• Kidney Cancer

  Journal of the National Comprehensive Cancer Network · 2009 · https://doi.org/10.6004/jnccn.2009.0043

Current projects

No projects listed.